Risk factors for immune checkpoint inhibitor–mediated cardiovascular toxicities
LI Yousif, EM Screever, D Versluis… - Current Oncology …, 2023 - Springer
Abstract Purpose of Review Immune checkpoint inhibitors (ICIs) have improved the field of
cancer, especially in patients with advanced malignancies. Nevertheless, cardiovascular …
cancer, especially in patients with advanced malignancies. Nevertheless, cardiovascular …
Immune checkpoint inhibitors and the heart
Immune checkpoint inhibitors (ICIs) represent a break-through treatment for a large number
of cancer types. This treatment is increasingly being recommended. ICIs are prescribed for …
of cancer types. This treatment is increasingly being recommended. ICIs are prescribed for …
Arrhythmic events associated with immune checkpoint inhibitors therapy: A real‐world study based on the Food and Drug Administration Adverse Event Reporting …
Y Liu, Y Chen, Z Zeng, A Liu - Cancer Medicine, 2023 - Wiley Online Library
Background Although arrhythmias have been reported in patients treated with immune
checkpoint inhibitors (ICIs), the association between arrhythmias and ICIs has not been …
checkpoint inhibitors (ICIs), the association between arrhythmias and ICIs has not been …
Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
F Wang, Q Wei, X Wu - Frontiers in Pharmacology, 2022 - frontiersin.org
Introduction: With the widespread application of Immune checkpoint inhibitors (ICIs), it is
important to explore the association between ICIs and cardiac arrhythmias and to …
important to explore the association between ICIs and cardiac arrhythmias and to …
Pancreatic adverse events associated with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis
Y Zhang, Y Fang, J Wu, G Huang, J Bin… - Frontiers in …, 2022 - frontiersin.org
Backgrounds: Immune checkpoint inhibitors (ICIs) are considered cornerstones of oncology
treatment with durable anti-tumor efficacy, but the increasing use of ICIs is associated with …
treatment with durable anti-tumor efficacy, but the increasing use of ICIs is associated with …
Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database
X Ren, G Zhang, G Li, Y Wang - BMC cancer, 2024 - Springer
Background Nervous system toxicity (NST) is one of the most frequent and dangerous side
effects of chimeric antigen receptor T-cell (CAR-T) therapy, which is an effective treatment for …
effects of chimeric antigen receptor T-cell (CAR-T) therapy, which is an effective treatment for …
Adverse events during pregnancy associated with entecavir and adefovir: new insights from a real-world analysis of cases reported to FDA adverse event reporting …
R Yang, N Yin, Y Zhao, D Li, X Zhang, X Li… - Frontiers in …, 2022 - frontiersin.org
Background: Due to the embryotoxicity found in animal studies and scarce clinical data in
pregnant women, it is still controversial whether entecavir (ETV) and adefovir dipivoxil (ADV) …
pregnant women, it is still controversial whether entecavir (ETV) and adefovir dipivoxil (ADV) …
Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the …
Z Fu, J Liu, C Zhang, H Hu, S Li, Y Zhang… - Frontiers in …, 2024 - frontiersin.org
Background: Immune checkpoint inhibitors (ICIs), including anti-PD-1, anti-PD-L1 and anti-
CTLA-4 antibodies, have become a standard treatment for multiple cancer types. However …
CTLA-4 antibodies, have become a standard treatment for multiple cancer types. However …
Tyrosine kinase inhibitors-associated interstitial lung disease used in non-small cell lung cancer: a pharmacovigilance analysis based on the FDA adverse event …
J Zhang, T Qiu, Y Zhou, S Wu… - Expert Opinion on Drug …, 2023 - Taylor & Francis
Background Interstitial lung disease (ILD) was a relatively common cause of drug-induced
mortality. However, the safety profile of the whole TKIs induced ILD was largely unknown …
mortality. However, the safety profile of the whole TKIs induced ILD was largely unknown …
Checkpoint-inhibitor induced Polyserositis with Edema
S Zierold, LS Akcetin, E Gresser, AM Maier… - Cancer Immunology …, 2022 - Springer
Background As immune checkpoint inhibitors (ICI) are increasingly being used due to
effectiveness in various tumor entities, rare side effects occur more frequently. Pericardial …
effectiveness in various tumor entities, rare side effects occur more frequently. Pericardial …